Interaction of fentanyl and buprenorphine in an experimental model of pain and central sensitization in human volunteers

Clinical Journal of Pain

Volumn 28, Issue 8, 2012, Pages 705-711

  Tröster, Andreas ^a   Ihmsen, Harald ^a   Singler, Boris ^a   Filitz, Jörg ^b   Koppert, Wolfgang ^b  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

analgesia; hyperalgesia; interaction; opioids; pharmacodynamic model

Indexed keywords

BUPRENORPHINE; FENTANYL; KAPPA OPIATE RECEPTOR ANTAGONIST; MU OPIATE RECEPTOR AGONIST; OPIATE; PLACEBO; SODIUM CHLORIDE;

ADULT; ANALGESIA; ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG INFUSION; HUMAN; HYPERALGESIA; MALE; NAUSEA; NORMAL HUMAN; PAIN; PAIN ASSESSMENT; PHARMACODYNAMICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SEDATION; SENSITIZATION; SIDE EFFECT; SINGLE DRUG DOSE; TRANSCUTANEOUS NERVE STIMULATION; TREATMENT OUTCOME;

ADULT; ANALGESICS, OPIOID; ANALYSIS OF VARIANCE; BUPRENORPHINE; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FENTANYL; HUMANS; HYPERALGESIA; INFUSIONS, INTRAVENOUS; MALE; PAIN MEASUREMENT; PAIN THRESHOLD; TRANSCUTANEOUS ELECTRIC NERVE STIMULATION; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84865658140     PISSN: 07498047     EISSN: 15365409     Source Type: Journal    
DOI: 10.1097/AJP.0b013e318241d948     Document Type: Article

References (32)

1. Moiniche S, Kehlet H, Dahl JB. A qualitative and quantitative systematic review of preemptive analgesia for postoperative pain relief: the role of timing of analgesia. Anesthesiology. 2002;96:725-741. (Pubitemid 34193516)
2. Celerier E, Rivat C, Jun Y, et al. Long-lasting hyperalgesia induced by fentanyl in rats: preventive effect of ketamine. Anesthesiology. 2000;92:465-472. (Pubitemid 30078345)
3. Guignard B, Bossard AE, Coste C, et al. Acute opioid tolerance: intraoperative remifentanil increases postoperative pain and morphine requirement. Anesthesiology. 2000;93:409-417. (Pubitemid 30620314)
4. Koppert W, Sittl R, Scheuber K, et al. Differential modulation of remifentanil-induced analgesia and postinfusion hyperalgesia by S-ketamine and clonidine in humans. Anesthesiology. 2003;99:152-159. (Pubitemid 36799046)
5. Cowan A. Update on the general pharmacology of buprenor-phine. In: Cowan A, Lewis JW, eds. Buprenorphine: Combatting Drug Abuse With a Unique Opioid. New York: Wiley-Liss; 1995:31-47.
6. Wnendt S, Kruger T, Janocha E, et al. Agonistic effect of buprenorphine in a nociceptin/OFQ receptor-triggered reporter gene assay. Mol Pharmacol. 1999;56:334-338. (Pubitemid 29347609)
7. Englberger W, Kogel B, Friderichs E, et al. Reversibility of opioid receptor occupancy of buprenorphine in vivo. Eur J Pharmacol. 2006;534:95-102. (Pubitemid 43384188)
8. Lutfy K, Eitan S, Bryant CD, et al. Buprenorphine-induced antinociception is mediated by mu-opioid receptors and compromised by concomitant activation of opioid receptorlike receptors. J Neurosci. 2003;23:10331-10337. (Pubitemid 37444610)
9. Koppert W, Ihmsen H, Korber N, et al. Different profiles of buprenorphine-induced analgesia and antihyperalgesia in a human pain model. Pain. 2005;118:15-22. (Pubitemid 41566581)
10. Koppert W, Dern SK, Sittl R, et al. A new model of electrically evoked pain and hyperalgesia in human skin: the effects of intravenous alfentanil, S(+)-ketamine, and lidocaine. Anesthesiology. 2001;95:395-402. (Pubitemid 32720728)
11. Gupta S, Sathyan G, Phipps B, et al. Reproducible fentanyl doses delivered intermittently at different time intervals from an electrotransport system. J Pharm Sci. 1999;88:835-841. (Pubitemid 29398554)
12. Lehmann KA. Opioids: overview on action, interaction and toxicity. Support Care Cancer. 1997;5:439-444. (Pubitemid 27494869)
13. Sittl R, Likar R, Nautrup BP. Equipotent doses of transdermal fentanyl and transdermal buprenorphine in patients with cancer and noncancer pain: results of a retrospective cohort study. Clin Ther. 2005;27:225-237. (Pubitemid 40462016)
14. Berenbaum MC. What is synergy? Pharmacol Rev. 1989;41: 93-141. (Pubitemid 20019599)
15. Bol CJ, Vogelaar JP, Tang JP, et al. Quantification of pharmacodynamic interactions between dexmedetomidine and midazolam in the rat. J Pharmacol Exp Ther. 2000;294:347-355. (Pubitemid 30434707)
16. Scott JC, Stanski DR. Decreased fentanyl and alfentanil dose requirements with age. A simultaneous pharmacokinetic and pharmacodynamic evaluation. J Pharmacol Exp Ther. 1987; 240:159-166. (Pubitemid 17235434)
17. Bullingham RE, McQuay HJ, Moore A, et al. Buprenorphine kinetics. Clin Pharmacol Ther. 1980;28:667-672. (Pubitemid 11254168)
18. Koppert W, Schmelz M. The impact of opioid-induced hyperalgesia for postoperative pain. Best Pract Res Clin Anaesthesiol. 2007;21:65-83. (Pubitemid 46478026)
19. Wala EP, Holtman JR Jr. Buprenorphine-induced hyperalgesia in the rat. Eur J Pharmacol. 2011;651:89-95.
20. Leander JD. Buprenorphine has potent kappa opioid receptor antagonist activity. Neuropharmacology. 1987;26:1445-1447. (Pubitemid 17154903)
21. Martin WR, Eades CG, Thompson JA, et al. The effects of morphine-and nalorphine-like drugs in the nondependent and morphine-dependent chronic spinal dog. J Pharmacol Exp Ther. 1976;197:517-532.
22. Lewis JW. Buprenorphine. Drug Alcohol Depend. 1985;14: 363-372. (Pubitemid 15149057)
23. Boas RA, Villiger JW. Clinical actions of fentanyl and buprenorphine. The significance of receptor binding. Br J Anaesth. 1985;57:192-196. (Pubitemid 15093410)
24. Pergolizzi J, Aloisi AM, Dahan A, et al. Current knowledge of buprenorphine and its unique pharmacological profile. Pain Pract. 2010;10:428-450.
25. Cowan A, Lewis JW, Macfarlane IR. Agonist and antagonist properties of buprenorphine, a new antinociceptive agent. Br J Pharmacol. 1977;60:537-545. (Pubitemid 8149539)
26. Sadee W, Rosenbaum JS, Herz A. Buprenorphine: differential interaction with opiate receptor subtypes in vivo. J Pharmacol Exp Ther. 1982;223:157-162. (Pubitemid 12033828)
27. Dahan A, Yassen A, Romberg R, et al. Buprenorphine induces ceiling in respiratory depression but not in analgesia. Br J Anaesth. 2006;96:627-632.
28. Cook PJ, James IM, Hobbs KE, et al. Controlled comparison of I.M. morphine and buprenorphine for analgesia after abdominal surgery. Br J Anaesth. 1982;54:285-290. (Pubitemid 12187738)
29. Muller H, Gerlach H, Gips H, et al. Intra-and postoperative interactions between the 2 opioids fentanyl and buprenorphine. Anaesthesist. 1986;25:125-129.
30. Freye E, Hartung E, Levy JV. No potentiation of fentanyl by use of transdermal buprenorphine in patients undergoing fast-track anesthesia for open-heart surgery. J Opioid Manag. 2005;1:162-167.
31. Kress HG. Clinical update on the pharmacology, efficacy and safety of transdermal buprenorphine. Eur J Pain. 2009;13:219-230.
32. Yassen A, Olofsen E, Romberg R, et al. Mechanism-based pharmacokinetic-pharmacodynamic modeling of the antinoci-ceptive effect of buprenorphine in healthy volunteers. Anesthesiology. 2006;104:1232-1242. (Pubitemid 43852957)